Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2133733 | 0.96 | USP30 (0.47) | USP30MAPTMEN1KMT2APOLB | |
| SCHEMBL2133873 | 0.92 | USP30 (0.49) | USP30MAPTMEN1KMT2APOLB | |
| SCHEMBL14035660 | 0.87 | USP30 (0.51) | USP30MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL25517300 | 0.85 | GLA (0.53) | USP30MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2131359 | 0.83 | FKBP1A (0.62) | USP30MAPTMEN1KMT2APOLB | |
| SCHEMBL2133807 | 0.81 | USP30 (0.51) | USP30MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL2132316 | 0.81 | USP30 (0.48) | USP30MEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL2132155 | 0.80 | SMN1; SMN2 (0.66) | MAPTMEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL2133127 | 0.80 | PDE4B (0.41) | USP30SMN1; SMN2DRD3 | |
| SCHEMBL25453440 | 0.79 | USP30 (0.54) | USP30MEN1KMT2APOLBDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912329-B2 | Composition for treatment of tuberculosis | BioVersys AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8912329-B2 | Composition for treatment of tuberculosis | BioVersys AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8912329-B2 | Composition for treatment of tuberculosis | BioVersys AG (CH) | 2014-12-16 | — | — | US | disclosed |
| EP-2445495-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | Bioversys AG (CH) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BioVersys AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BioVersys AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BioVersys AG (CH) | 2012-04-26 | — | — | US | disclosed |
| WO-2010149761-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BIOVERSYS GMBH (CH) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010149761-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BIOVERSYS GMBH (CH) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | PRMT7, NCOA3, PRMT3 | USP30 3636/4885MAPT 2520/4885MEN1 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.